Lv31
350 积分 2025-04-13 加入
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
6小时前
已完结
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
11天前
已完结
The changing therapeutic landscape of small-cell lung cancer
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
1个月前
已完结
Small Cell Lung Cancer
2个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
4个月前
已关闭
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
4个月前
已关闭
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
6个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1年前
已完结
皖公网安备34019202002308
